Form 4 for TARS Tarsus Pharmaceuticals, Inc.
Accepted 2025-03-18 00:00:00 ET · period of report 2025-03-15 · accession 0001819790-25-000046 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-18 | 2025-03-15 | TARS | Azamian Bobak R. | Pres, CEO, Board COB, Dir | M - OptEx | — | +51.4K | 77.9K | +194% | — |
| DM | 2025-03-18 | 2025-03-15 | TARS | Azamian Bobak R. | Pres, CEO, Board COB, Dir | M - OptEx | $0.00 | -51.4K | 11.3K | -82% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-15 | M | A | 51,395 | — | 77,851 | D | — | — | (F1) The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). |
| 2 | Derivative | Restricted Stock Units | 2025-03-15 | M | D | 16,975 | $0.00 | 33,950 | D | — · — to — | 16,975 Common Stock | (F3) Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. (F5) RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. |
| 3 | Derivative | Restricted Stock Units | 2025-03-15 | M | D | 23,121 | $0.00 | 69,364 | D | — · — to — | 23,121 Common Stock | (F3) Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. (F6) RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service. |
| 4 | Derivative | Restricted Stock Units | 2025-03-15 | M | D | 11,299 | $0.00 | 11,300 | D | — · — to — | 11,299 Common Stock | (F3) Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. (F4) RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025 and 2026, subject to the Reporting Person's continuous service. |